ZBIO Stock Forecast & Price Target

Zenas BioPharma is poised to potentially become a leader in the autoimmune disease space with its promising pipeline of transformative immunology-based therapies, including the current Phase 3 development of its oral CNS-penetrant BTK inhibitor, orelabrutinib, for primary and non-active secondary progressive MS. The company's recent positive updates on its bifunctional monoclonal antibody, obexelimab, in relapsing multiple sclerosis (RMS) patients, combined with its anticipated BLA submission for IgG4-RD and Phase 2 SLE data, demonstrate its potential for growth and could lead to a compelling risk/benefit proposition within the limited treatment options for progressive MS. Further catalysts to watch include the initiation of the Phase 3 naSPMS trial for orelabrutinib and potential differentiation from other BTK inhibitors on the market.

Zenas BioPharma is a clinical-stage biopharmaceutical company with a negative outlook due to its high research and development costs, as evidenced by the reported R&D expenses of $60.4 million and net loss of $81.0 million for the first quarter of 2026, and lack of profitable drugs on the market. Additionally, the company's reliance on a single reportable segment and its pipeline of early-stage drug candidates create a risky investment opportunity.